References
- Hunger SP, Lu X, Devidas M et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children’s oncology group. J. Clin. Oncol. 30(14), 1663–1669 (2012).
- Roy A, Cargill A, Love S et al. Outcome after first relapse in childhood acute lymphoblastic leukaemia – lessons from the United Kingdom R2 trial. Br. J. Haematol. 130(1), 67–75 (2005).
- Reismüller B, Attarbaschi A, Peters C et al.; Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria – a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br. J. Haematol. 144(4), 559–570 (2009).
- Mullighan CG, Phillips LA, Su X et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 322(5906), 1377–1380 (2008).
- Yang JJ, Bhojwani D, Yang W et al. Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood 112(10), 4178–4183 (2008).
- Hogan L, Meyer J, Yang J et al. Integrated genomic analysis of relapsed childhood acute lymphoblastic leukemia reveals therapeutic strategies. Blood 118(19), 5218–5226 (2011).
- Meyer JA, Wang J, Hogan LE et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat. Genet. 45(3), 290–294 (2013).
- Tzoneva G, Perez-Garcia A, Carpenter Z et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat. Med. 19(3), 368–371 (2013).
- Spychala J, Madrid-Marina V, Fox IH. High Km soluble 5´-nucleotidase from human placenta. Properties and allosteric regulation by IMP and ATP. J. Biol. Chem. 263(35), 18759–18765 (1988).
- Tozzi MG, Camici M, Allegrini S et al. Cytosolic 5′-nucleotidase/phosphotransferase of human colon carcinoma. Adv. Exp. Med. Biol. 309B, 173–176 (1991).
- Jordheim LP, Marton Z, Rhimi M et al. Identification and characterization of inhibitors of cytoplasmic 5´-nucleotidase cN-II issued from virtual screening. Biochem. Pharmacol. 85(4), 497–506 (2013).